Key statistics
On Tuesday, SAB Biotherapeutics Inc (SABS:NAQ) closed at 2.67, 23.61% above the 52 week low of 2.16 set on Aug 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.74 |
---|---|
High | 2.79 |
Low | 2.60 |
Bid | 2.81 |
Offer | 2.90 |
Previous close | 2.74 |
Average volume | 26.16k |
---|---|
Shares outstanding | 9.23m |
Free float | 7.46m |
P/E (TTM) | -- |
Market cap | 24.64m USD |
EPS (TTM) | -5.69 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 20:37 BST.
More ▼
Announcements
- SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
- SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
- SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
- SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
- SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
- SAB BIO Appoints Lucy To as Chief Financial Officer
- SAb Biotherapeutics Rebrands as SAB BIO
- SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
- SAB Biotherapeutics Announces Departure of Chief Financial Officer
- FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
More ▼